De-Risk Development And Manufacture Of Bispecific Antibodies With Lonza

By Alice Harrison, Director, Global Technical & CMC, Analytics, Lonza

There is growing demand for multi-chain protein biotherapeutics such as bispecific antibodies (bsAbs) which offer promising treatments for cancers and other diseases. But assembling and expressing bsAbs to advance them for first-in-human (FIH) trials comes with a set of unique challenges.

This article will explore how to meet those challenges head-on by partnering with a contract development and manufacturing organization (CDMO) that has proven expertise and a toolbox of technologies designed for peak performance with these novel molecular formats.